Promethera's HepaStem cell therapy safe in liver failure study

Promethera said its HepaStem cell therapy comprising human adult liver-derived mesenchymal stem cells achieved a positive safety profile and improved three measures of liver disease severity in a Phase IIa trial to treat acute-on-chronic liver failure (ACLF).

Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) said IV HepaStem led to no clinically significant changes in platelet count, fibrinogen levels or coagulation factors following infusion, and no treatment-related adverse events were reported. The company also said HepaStem showed "trends in efficacy" with improvements in Model for End-Stage Liver Disease (MELD) score, Child-Pugh score and bilirubin levels at day 28 and up to three months after initiating treatment...